INOVIO Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2012. The interim financial statements are unaudited. Inovio develops DNA vaccines and electroporation delivery technology; all human product candidates remained in research and development, with no approved products or product-sale revenue.
Financial performance and position
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $0.855 million | $2.638 million | $2.984 million | $8.163 million |
| Operating loss | $6.292 million | $6.336 million | $17.266 million | $15.859 million |
| Net loss | $6.632 million | $4.557 million | $19.042 million | $9.816 million |
| Net loss per share | $0.05 | $0.04 | $0.14 | $0.08 |
- Revenue mix: Nine-month revenue included $2.481 million in grants and miscellaneous revenue, $0.387 million in license and milestone revenue, and $0.116 million from affiliated-entity collaborative R&D arrangements.
- Expenses: Nine-month R&D expense was $13.542 million and G&A expense was $7.859 million. The filing does not present a meaningful gross margin; product sales had not begun.
- Cash flow: Operating activities used $16.784 million in the first nine months of 2012, versus $15.222 million in 2011. Investing activities provided $2.797 million and financing activities provided $1.226 million. Cash and cash equivalents fell $12.761 million to $4.589 million.
- Liquidity: Short-term investments were $10.555 million, giving cash plus short-term investments of about $15.144 million. Working capital was $5.7 million, down from $20.9 million at December 31, 2011. Total current liabilities were $11.276 million.
- Debt and equity: The filing does not disclose interest-bearing borrowings. It reports $6.163 million of current warrant liabilities, remeasured at fair value. Stockholders’ equity totaled $31.280 million; accumulated deficit was $229.101 million.
Changes versus comparable periods
- Nine-month revenue declined 63% year over year, primarily because grant revenue was lower. Management cited timing of NIAID contract payments and no 2012 revenue from the PATH malaria program during the reported periods.
- Nine-month R&D expense declined about 15%, mainly reflecting lower NIAID-related direct costs, biologics manufacturing and laboratory processing, and outside services; increased compensation partly offset the reductions.
- Nine-month operating loss widened about 9%, and net loss nearly doubled. The 2011 comparison included a $7.578 million gain from lower warrant fair value; in 2012, warrant remeasurement instead produced a $1.067 million expense. This noncash item was a major contributor to the net-loss comparison.
- Cash used in operations increased from the prior-year period. Financing cash inflows fell sharply from $24.322 million in 2011, when the company completed equity financings, to $1.226 million in 2012.
Outlook, commentary and risks
- Management expected cash, cash equivalents and short-term investments to meet planned working-capital requirements into the third quarter of 2013, and said further outside financing would be needed beyond that period. The company stated it may never achieve positive cash flow and prepared its statements on a going-concern basis.
- In June 2012, Inovio established an at-the-market equity program for up to $25 million gross proceeds. It sold 2.087 million shares through September 30 for $1.2 million net proceeds. After quarter-end, it sold another 2.308 million shares for $1.5 million net proceeds through October 15.
- VGX International agreed to fund IND-enabling and initial Phase I/II studies of hepatitis B and C vaccine candidates in exchange for specified Asian marketing rights. A PATH agreement amendment was signed in October 2012 for $887,000 in feasibility, process-development and cell-bank work.
- Key risks include ongoing losses and financing dependence; uncertain clinical and regulatory outcomes; manufacturing and trial delays; reliance on grants and a limited number of collaborators; competition; intellectual-property disputes; and possible dilution from future equity issuance. The company had no approved human products and did not expect product-sale revenue for at least several years.
- Unusual items and contingencies: warrant fair values rely on significant estimates and caused material earnings volatility. Inovio also reported $2.0 million of scheduled OncoSec payments for which it recorded no receivable because collection was not reasonably assured. No legal proceedings were reported as applicable. Management stated disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether the reported cash runway and subsequent financing are sufficient given the $16.8 million nine-month operating cash use and stated need for additional capital.
- Progress, timelines, funding responsibilities and commercial rights under the clinical programs and collaboration agreements, particularly with VGX International and government grantors.
- Sources and timing of future revenue, including NIAID contract funding and the October PATH amendment.
- Potential earnings and balance-sheet effects of warrant remeasurement, the OncoSec payment extensions, and the unrecorded scheduled payments.
- Share-count dilution: 139,363,780 common shares were outstanding on November 2, 2012; the filing also describes substantial outstanding options and warrants.